Takeo Endo
Overview
Explore the profile of Takeo Endo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
299
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Numata T, Nakamura R, Shiozawa T, Watanabe H, Okauchi S, Ogara G, et al.
Cancer Diagn Progn
. 2025 Jan;
5(1):105-114.
PMID: 39758245
Background/aim: Atezolizumab, one of the anti-PD-L1 antibodies, targets PD-L1 expressed on cancer cells and antigen-presenting cells. This immune checkpoint inhibitor is now commonly used in combination with chemotherapy. The objectives...
2.
Maezawa Y, Taguchi M, Kawakami T, Inui T, Okauchi S, Numata T, et al.
Tuberk Toraks
. 2024 Jun;
72(2):107-113.
PMID: 38869202
Introduction: In addition to the two common epidermal growth factor receptor (EGFR) mutations, there are many uncommon mutations. Due to the high number of uncommon types, as well as the...
3.
Ano S, Kikuchi N, Okauchi S, Numata T, Nakamura R, Shiozawa T, et al.
Anticancer Res
. 2024 May;
44(6):2725-2730.
PMID: 38821613
Background/aim: Atezolizumab, an anti-PD-L1 antibody, has been increasingly administered in combination with chemotherapy to patients with small cell lung cancer (SCLC). This study aimed to determine how patients with extensive...
4.
Maezawa Y, Taguchi M, Kawakami T, Inui T, Okauchi S, Numata T, et al.
Anticancer Res
. 2024 Mar;
44(4):1751-1757.
PMID: 38537995
Background/aim: The median age of subjects in many clinical trials of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor conducted to date has been approximately 60 years. However, it is not...
5.
Kurihara S, Nakamura R, Yoneyama S, Takase S, Hatori T, Yamagishi T, et al.
Anticancer Res
. 2024 Feb;
44(2):767-779.
PMID: 38307568
Background/aim: The association between resected non-small cell lung cancer (NSCLC) and long-term outcomes of muscle mass depletion and muscle weakness has also not been well documented. This study evaluated whether...
6.
Tamura T, Numata T, Yanai H, Nakamura R, Shiozawa T, Watanabe H, et al.
Anticancer Res
. 2023 Sep;
43(10):4583-4591.
PMID: 37772562
Background/aim: Atezolizumab, an anti-programed death-ligand 1 monoclonal antibody, targets programed death-ligand 1 expressed on cancer cells and antigen-presenting cells and is now commonly used in combination with chemotherapy. We conducted...
7.
Okauchi S, Ohara G, Shiozawa T, Watanabe H, Numata T, Nakamura R, et al.
In Vivo
. 2023 Aug;
37(5):2203-2209.
PMID: 37652502
Background/aim: Atezolizumab is a monoclonal antibody that targets programmed death-ligand 1 (PD-L1) expressed on cancer cells derived from various organs and antigen-presenting cells and is currently commonly used in combination...
8.
Arai N, Nakajima M, Matsuyama M, Matsumura S, Yazaki K, Sakai C, et al.
Am J Respir Cell Mol Biol
. 2023 Aug;
69(2):242-246.
PMID: 37526393
No abstract available.
9.
Takata S, Morikawa K, Tanaka H, Itani H, Ishihara M, Horiuchi K, et al.
Ther Adv Med Oncol
. 2023 Jun;
15:17588359231177021.
PMID: 37323187
Background: The exosome-focused translational research for afatinib (EXTRA) study is the first trial to identify novel predictive biomarkers for longer treatment efficacy of afatinib in patients with epidermal growth factor...
10.
Kogure Y, Kada A, Hashimoto H, Atagi S, Takiguchi Y, Saka H, et al.
JTO Clin Res Rep
. 2023 Jun;
4(6):100514.
PMID: 37304652
Introduction: In the CAPITAL study, a randomized phase 3 study, wherein carboplatin plus nab-paclitaxel treatment was compared with docetaxel treatment for older patients with squamous-cell lung cancer, the former became...